Navigation Links
Switching drugs regularly improves HIV treatment

NEW YORK (Reuters Health) - When HIV-infected patients alternated their drug regimen every three months, their virus levels stayed down longer than when one regimen was administered continuously.
That news comes from the SWATCH (SWitching Antiviral Therapy Combination against HIV-1) study. Dr. Javier Martinez-Picado, of Hospital Germans Trias I Pujol in Badalona, Spain, and others examined this alternating strategy among HIV patients who //were randomized to one of three regimens.
Regimen A consisted of continuous treatment with didanosine, stavudine, and efavirenz. For regimen B, patients were administered zidovudine, lamivudine and nelfinavir. In regimen C, the patients alternated between the other two regimens every 3 months. The results are reported in the Annals of Internal Medicine .
Response to treatment was similar in patients receiving regimen A or regimen B, so the researchers pooled these two groups when evaluating the results.
The rate of virologic failure - that is, a rise in the amount of virus in the blood above a defined level - was 3.5 higher during the following year in the pooled group than in the alternating therapy group.
Dr. Martinez-Picado's group concludes, "Proactive switching and alternation of antiretroviral regimens with drugs that have different resistance profiles might extend the overall long-term effectiveness of first- and second-line treatment options."
In an editorial, Dr. Michael Saag, of the University of Alabama at Birmingham, points out that current drug regimens are more efficacious than the ones used in the SWATCH study.
However, he agrees with Dr. Martinez-Picado's group that further study of proactive switching seems warranted, but that the strategy should not be routine at this time..


'"/>




Page: 1

Related medicine news :

1. Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer
2. Switching Genes to Overdrive Improves Muscular Dystrophy Symptoms in Mice
3. Cancer drugs in development nearly doubled since 1995
4. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
5. African HIV strains more resistant to anti HIV drugs
6. Right drugs drastically cut stroke risk
7. Relating heart protection and antihypertensive drugs
8. Enzyme may be target for obesity drugs
9. New HIV cases resist drugs
10. Relief to pregnant women using fertility drugs
11. AIDS drugs linked to heart attack risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... ... now promoting to the US market its advanced highly customizable contact technology solutions. ... ODU TURNTAC®. These advanced technologies are ideal for a wide range of applications ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance ... residents in the Sacramento/Folsom region, is initiating a charity event to raise support ... Choice Another Chance treatment center in Sacramento works to provide area teens and ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A. Kevin ... owners and families throughout the Five Boroughs, is launching a charity drive to raise ... to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: ... previously disclosed underwritten public offering of units with ... sole book-running manager, Roth Capital Partners acted as ... co-manager for the offering. "This financing ... proceeds, allowing us to continue advancing bremelanotide for ...
(Date:12/7/2016)... Md. , Dec. 7, 2016  Northwest ... or the "Company"), a biotechnology company developing DCVax® ... announced that the Nasdaq Staff has not accepted ... of Listing Rules previously reported, and the Company ... withdraw the Company,s common stock from listing on ...
(Date:12/7/2016)... , December 7, 2016 ... Trial Management System (CTMS) Market, by Components (Software, ... Site), End-users (Pharmaceutical and Biotechnology Companies, Clinical Research ... Share, Size and Forecast to 2022", published by ... system (CTMS) market is expected to grow at ...
Breaking Medicine Technology: